Swiss Aerospace & Defense Stock News

Holcim (SWX:HOLN) has launched the Czech Republic's first calcined clay production line to supply its low-carbon ECOPlanet cement range. The new facility is designed to use calcined clay as a partial clinker substitute, aiming to lower the carbon intensity of cement. Management positions this Czech project as part of Holcim's broader push to scale low-carbon building materials across key European markets. Holcim's launch of a Czech calcined clay line for ECOPlanet cement is worth weighing...

In September 2026, European markets have been navigating a complex landscape marked by rising inflation concerns and increased geopolitical tensions, which have driven oil prices higher and put upward pressure on government bond yields. Amidst these challenges, identifying growth companies with high insider ownership can be appealing to investors seeking resilience and alignment of interests in volatile times.

Cash is suddenly interesting again. Short term rates are higher, central banks are tapping the brakes more carefully, and market swings are pushing more money into brokers, custodians, and money market platforms that sit closest to idle cash. That shift can reshape revenue streams and reprice risk. This article walks through three stocks from our Global Cash and Money-Market Platform Beneficiaries screener that appear well positioned for this new focus on cash. The stocks below are just a...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Amrize (SWX:AMRZ) has been in focus after the board moved Mario Gross into the role of President, Building Envelope, following Jake Gosa’s resignation. This change places leadership of a core division under new oversight. That leadership reshuffle comes as Amrize trades at CHF32.07, with the share price down 15.3% over the past month and 28.5% over the last quarter, while the 1-year total shareholder return has declined 23.4%, a pattern that points to fading momentum as investors reassess...

Novartis reported Phase III REMODEL-1/-2 data showing that remibrutinib reduced annualized relapse rates and MRI lesions versus teriflunomide in adults with relapsing multiple sclerosis, with a favorable safety profile and plans to seek global regulatory approval. The remibrutinib readout adds another late-stage asset alongside existing priority brands and reinforces Novartis' focus on high-value immunology and neuroscience therapies that can support its broader push for higher quality...

Medacta Group reported half year 2026 sales of €368.17 million and net income of €41.86 million, while also issuing full year guidance targeting 10% to 14% revenue growth in constant currency. The mix of higher sales and lower earnings, combined with explicit revenue growth targets, highlights how Medacta Group is balancing expansion with profitability pressures. We will now assess how Medacta Group's investment narrative could shift in light of its new 10% to 14% constant currency revenue...

Amidst escalating geopolitical tensions and rising inflation concerns, European markets have recently faced headwinds, with the STOXX Europe 600 Index declining as energy prices surged. In such a challenging environment, growth companies with significant insider ownership can offer potential resilience and alignment of interests between management and shareholders.

Ypsomed Holding (SWX:YPSN) has drawn fresh attention after announcing its first US advanced manufacturing facility in Holly Springs, North Carolina, a project tied directly to its self injection systems expansion. Recent trading has been choppy. The 7 day share price return is down 8.16% and the 30 day move is down 13.45%, even though the year to date share price return is 9.09% and the 5 year total shareholder return is 152.39%. This shows that longer term momentum remains intact as...

Dätwyler Holding AG ( VTX:DAE ), is not the largest company out there, but it received a lot of attention from a...

Trade routes are being redrawn as BRICS countries push new supply chains, payment rails, and material corridors, and that ripple runs straight through the custody banks and FX specialists that keep money and securities moving. Investors watching those plumbing changes risk missing the story if they only track headlines. This article breaks down three stocks from our Global Custody Banks and FX/Risk-Management Providers screener that appear closely tied to these shifts, and explains how their...

Alcon stock reacts to UNITY M surgical microscope launch Alcon (SWX:ALC) just moved its UNITY platform forward with the commercial launch of UNITY M, a premium ophthalmic surgical microscope now rolling out in the U.S., Japan and other key markets. That product push comes as Alcon’s share price has been under pressure, with the stock at CHF55.0 and a 30-day share price return of down 9.36%. The 90-day share price return is up 4.72% and the 1-year total shareholder return is down 10.89%,...

In September 2026, European markets are navigating increased inflation concerns and rising bond yields, driven by geopolitical tensions and energy price surges. Amid this backdrop, growth companies with high insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.

Logitech International recently unveiled the MX Keypad for developers, a customizable AI-focused control center with GitHub Copilot, Claude Code, and OpenAI Codex integrations, plus three free months of GitHub Copilot Pro+ and a sustainability-focused design priced at $99.99/€99.99. The MX Keypad pushes Logitech International deeper into software-enabled peripherals by tying physical devices to AI agents, SDK-driven extensions, and a large existing installed base of compatible hardware. We...

Roche Holding (SWX:ROP) collaborator MediLink reported positive Phase III results for Tam-Peli in relapsed small-cell lung cancer. The Tam-Peli trial showed significant gains in overall survival and response rates for patients who had already relapsed after prior therapy. Genentech, Roche’s US biotech unit, received FDA Priority Review for Enspryng to treat MOGAD, a rare autoimmune disease with no approved therapies. The Tam-Peli Phase III success and Enspryng Priority Review sit alongside...

Medacta Group SA ( VTX:MOVE ) shareholders are probably feeling a little disappointed, since its shares fell 9.8% to...

Avolta (SWX:AVOL) just locked in extended contracts with Grupo Aeroportuario del Pacífico across four major Mexican airports, securing exposure to more than 30 million travelers a year and future store expansion opportunities. Avolta’s latest contract wins and its September 2026 blockchain payment pilot come against a mixed price backdrop, with the share price at CHF43.6 after a 30 day share price return down 12.31% and a 3 year total shareholder return of 22.61%, which points to longer term...

Novartis (SWX:NOVN) is under pressure after the Phase III HARBOR trial of delpacibart etedesiran in myotonic dystrophy type 1 missed its primary endpoint, a setback that triggered a sharp share price reaction. That disappointment landed on top of an already bruising week for Novartis, with the 7-day share price return down about 13.5% and the 30-day share price return lower by roughly 9.8% as investors reassessed pipeline risk after back-to-back late-stage trial failures. Yet over a longer...

UBS Group (SWX:UBSG) has just wrapped up a large debt tender program, agreeing to repurchase about $7.93b of outstanding notes after lifting its maximum purchase size to roughly $5.85b in total consideration. UBS Group’s shares trade at CHF44.56 after a 1 day share price return of 1.39% and a 90 day share price return of 14.55%. The 1 year total shareholder return of 41.25% and 5 year total shareholder return of 233.69% point to strong momentum that recent debt tender and issuance activity...

Avolta AG recently launched a pilot blockchain-based payment system that settles purchases directly with customers within seconds and, in a separate move, Dufry International AG extended agreements that keep Avolta operating and expanding across four major Mexican airports handling over 30 million passengers a year. The combination of faster in-store payments and secured, expanding footprints in long-standing Mexican airport partnerships tightens Avolta's grip on high-traffic travel hubs...

Logitech International (SWX:LOGN) drew fresh attention this week after shareholders approved amendments to the Articles of Incorporation at the 8 September 2026 AGM, putting the company’s governance framework in focus for investors. The share price has eased in recent months, with a 30-day share price return of down 4.9% and a 90-day share price return of down 8.9%, even as Logitech International rolled out the MX Keypad launch and new workplace research alongside the governance changes...

Barry Callebaut presented at Barclays' Global Consumer Staples Conference in Boston and outlined how a well supplied cocoa market supports its current risk management approach after recent weather and disease concerns in West Africa. The proposed 6% pay increase for Ghanaian cocoa farmers, combined with Ivory Coast's larger harvest, highlights how farmer incomes and regional crop quality can directly reshape Barry Callebaut's sourcing costs and supply security. This article will examine how...

Romande Energie Holding reported first half 2026 revenue of CHF 407.16 million and net income of CHF 46.4 million, alongside higher electricity and thermal generation volumes compared with the prior year period. Construction of the 10 MW Les Muids wind farm in France adds to Romande Energie Holding's 240 MW gross renewable portfolio across 14 operating assets and several projects under development. The combination of stronger first half profitability and the new Les Muids wind farm under...

UBS Group has delivered a very strong 5 year share price gain, yet current valuation checks still suggest the stock trades at a discount to what its fundamentals might justify. The Excess Returns intrinsic value estimate and market multiple view both lean toward undervaluation, even after this extended run. Over the past 5 years, UBS Group has returned about 226%, which puts pressure on any argument that it remains an obvious bargain without further analysis. Recent moves such as expanding...